Key Takeaways & Executive Findings
- •• Developed an in vitro TurboID proximity labeling assay to identify protoRAG-interacting proteins in amphioxus. • The assay uses recombinant TurboID-tagged BbRAG1L/BbRAG2L proteins incubated with amphioxus tissue lysates. • Biotinylated proteins are enriched and analyzed by LC-MS/MS, enabling the identification of candidate cofactors. • This method bypasses the need for transgenic amphioxus, facilitating studies on RAG evolution and regulation.
Abstract
The recombination-activating gene (RAG)-mediated V(D)J rearrangement is essential for adaptive immunity in jawed vertebrates. RAG evolved from an invertebrate RAG-like (RAGL) transposase, with the amphioxus protoRAG (BbRAG1L/BbRAG2L) serving as a key model. However, the regulatory mechanisms of protoRAG remain unclear. Here, we developed an in vitro proximity labeling assay using TurboID fused to BbRAG1L or BbRAG2L to identify interacting proteins from amphioxus hepatic cecum and colon lysates. The fusion proteins were expressed in Expi293F cells, purified, and incubated with amphioxus lysates in the presence of biotin and ATP. Biotinylated proteins were enriched via streptavidin beads and analyzed by LC-MS/MS. This approach enables the identification of protoRAG-interacting proteins without the need for transgenic amphioxus, providing a valuable tool to study the evolution of RAG regulation.
1. Introduction
The recombination-activating gene (RAG)-mediated V(D)J rearrangement mechanism is essential for generating the diversity of the adaptive immune system in jawed vertebrates. The RAG1 and RAG2 proteins form a tetrameric complex that recognizes and cleaves pairs of recombination signal sequences (RSSs). In jawed vertebrates, the N-terminal region of RAG1 and the C-terminal region of RAG2 are critical for the regulation of physiological function and enhancement of recombination accuracy. Moreover, the intracellular activity of RAG1/2 is rigorously regulated and is thought to represent the aspect shaped by host coevolution. However, these regulatory mechanisms remain incompletely understood, impeding our deeper understanding of the physiological functions of RAG.
Previous studies have shown that jawed vertebrate RAG evolved from invertebrate RAG-like (RAGL) transposases and underwent key structural changes during evolution. RAGL genes have been identified in multiple invertebrate species, but from Branchiostoma belcheri (Bb), the RAG-like protein in Bb amphioxus (BbRAG1L) and the RAG2-like protein in Bb amphioxus (BbRAG2L) are among the most extensively characterized to date. Lancelets (amphioxus) represent the most basal extant chordates (cephalochordates) that diverged from the other two chordate lineages (urochordates and vertebrates). Consequently, amphioxus has been considered a “living fossil” for studying the origins and evolution of adaptive immunity. Homologs of the core structural domain of RAG1 were discovered in the amphioxus genome in 2005, and the homologs were subsequently shown to exhibit recombinase activity in cooperation with murine-derived RAG2. A large number of transposon genes were then identified in the amphioxus genome, followed by the identification of target site duplication (TSD) and terminal inverted repeat (TIR) sequences in the amphioxus genome. Notably, BbRAG2L lacks the C-terminal region present in murine RAG2, including the acidic hinge and PHD domain. BbRAG1L coupled with BbRAG2L displays significant transposition activity in vitro and in human cell lines. In contrast, vertebrate RAG exhibits limited transposon activity in vitro and extremely low transposon activity in vivo. This leads to the question of how RAG lost its transposase activity during evolution. Structural comparison and functional experiments of BbRAGL (protoRAG) and vertebrate RAG have revealed that vertebrates undergo essential adaptive changes to eliminate the primitive transposase activity of protoRAG. Research on BbRAGL has therefore provided strong support for the hypothesis that RAG originated from a domesticated transposon.
Loading authentic research manuscript (Pages 1–5)...
LU Qingyi, XU Jie, HONG Junye, XIAO Enfan, WEI Qiuzhu, SUN Yuhe, ZHAO Zihan, ZHANG Yuhang, HUANG Guangrui (2026). Development of an in vitro TurboID labeling assay for the detection of protoRAG-interacting proteins in the amphioxus. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2026030
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the purpose of the in vitro TurboID labeling assay?
The assay is designed to identify proteins that interact with protoRAG (BbRAG1L/BbRAG2L) in amphioxus, providing insights into the regulation and evolution of RAG.
How does the TurboID labeling work in this assay?
TurboID is a biotin ligase fused to BbRAG1L or BbRAG2L. When incubated with amphioxus lysates and biotin, it biotinylates nearby proteins, which are then enriched and identified by mass spectrometry.
Why is amphioxus used in this study?
Amphioxus is a basal chordate and a model for studying the evolution of adaptive immunity. Its RAG-like proteins (protoRAG) are considered ancestors of vertebrate RAG.
What are the advantages of this in vitro approach?
It avoids the technical challenges of generating transgenic amphioxus and allows for controlled labeling conditions, making it easier to identify candidate interacting proteins.
What are the potential applications of this assay?
The assay can be used to map the interaction networks of protoRAG, compare them with vertebrate RAG, and identify cofactors that regulate transposition versus recombination.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.